Nawa Y, Takenaka K, Shinagawa K, Deguchi S, Matsumura N, Koyama S, Hiramatsu Y, Omoto E, Yoshino T, Harada M
Second Department of Internal Medicine, Okayama University Medical School, Japan.
Bone Marrow Transplant. 1999 Jun;23(12):1321-2. doi: 10.1038/sj.bmt.1701803.
CD56+ angiocentric lymphoma has currently been recognized as a distinct clinical entity which is the prototype of the putative NK cell lymphomas. A 16-year-old Japanese girl with advanced CD56+ angiocentric lymphoma received high-dose chemotherapy supported with syngeneic peripheral blood stem cell transplantation (PBSCT). Prior to syngeneic PBSCT, she received six cycles of conventional chemotherapy before transplantation, resulting in a partial response. PBSC were mobilized with granulocyte colony-stimulating factor (G-CSF) and collected from her identical twin. High-dose cyclophosphamide, MCNU, etoposide, and carboplatin were used for pretransplant conditioning. Syngeneic PBSCT was well tolerated. She achieved complete remission and is now surviving in continuous complete remission for more than 30 months after syngeneic PBSCT. Thus, marrow-ablative chemotherapy facilitated by autologous or allogeneic PBSCT should be considered as part of the primary therapy for poor prognosis NK cell lymphomas.
CD56+血管中心性淋巴瘤目前已被公认为一种独特的临床实体，是假定的自然杀伤（NK）细胞淋巴瘤的原型。一名患有晚期CD56+血管中心性淋巴瘤的16岁日本女孩接受了同基因外周血干细胞移植（PBSCT）支持的大剂量化疗。在同基因PBSCT之前，她在移植前接受了六个周期的传统化疗，产生了部分缓解。通过粒细胞集落刺激因子（G-CSF）动员外周血干细胞，并从她的同卵双胞胎中采集。移植前预处理使用了大剂量环磷酰胺、氯乙基亚硝脲、依托泊苷和卡铂。同基因PBSCT耐受性良好。她实现了完全缓解，目前在同基因PBSCT后持续完全缓解超过30个月。因此，由自体或异基因PBSCT促进的骨髓清除性化疗应被视为预后不良的NK细胞淋巴瘤主要治疗的一部分。
